Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular

This page shows the latest cardiovascular news and features for those working in and with pharma, biotech and healthcare.

Evenity back on track with FDA panel blessing in osteoporosis

Evenity back on track with FDA panel blessing in osteoporosis

While the FDA still has the final say on full approval, the bone-building drug seems to have finally shaken off the cardiovascular safety concerns that caused the agency to reject ... to a much higher risk of cardiovascular side effects than the

Latest news

  • AZ’s Sean Bohen to exit after business overhaul; report AZ’s Sean Bohen to exit after business overhaul; report

    company restructured around two divisions – cancer and biopharmaceuticals including cardiovascular, diabetes and respiratory drugs. ... Immunocore, and Ludovic Helfgott – AZ’s head of cardiovascular and metabolic diseases – is set to join Novo

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    which found that the drug cut the risk of heart attacks and stroke by 25% in high-risk cardiovascular patients. ... The results rivalled the efficacy seen in cardiovascular outcomes trials for Amgen’s PCSK9 antibody Repatha (evolocumab), and

  • China first market to approve AZ’s kidney drug roxadustat China first market to approve AZ’s kidney drug roxadustat

    ESAs directly stimulate red blood cell production but can cause blood clots and other cardiovascular side effects. ... Meanwhile, a much-anticipated readout from a safety analysis focusing on major adverse cardiovascular events (MACE) – which could be

  • Novartis withdraws EU filing for canakinumab Novartis withdraws EU filing for canakinumab

    Further setback for cardiovascular blockbuster potential. Novartis has withdrawn the EMA filing for its drug canakinumab as a potential cardiovascular treatment after the EU regulator followed its US counterpart in raising ... The Swiss pharma giant had

  • Shire bags US approval for constipation drug Motegrity Shire bags US approval for constipation drug Motegrity

    The positive panel vote laid to rest lingering concerns about the safety of prucalopride that first surfaced more than a decade ago and centred around potential cardiovascular reactions linked to other

More from news
Approximately 33 fully matching, plus 819 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 68 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 52 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 43 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics